Disorders of other endocrine glands (E20-E35)
E20Hypoparathyroidism
Excludes 1: Di George's syndrome (D82.1)
› postprocedural hypoparathyroidism (E89.2)
› tetany NOS (R29.0)
› transitory neonatal hypoparathyroidism (P71.4)
E20.0Idiopathic hypoparathyroidism
E20.1Pseudohypoparathyroidism
E20.8Other hypoparathyroidism
E20.81Hypoparathyroidism due to impaired parathyroid hormone secretion
E20.810Autosomal dominant hypocalcemia
› Autosomal dominant hypocalcemia type 1 (ADH1)
› Autosomal dominant hypocalcemia type 2 (ADH2)
Code Also: , if applicable, any associated conditions, such as:
› calculus of kidney (N20.0)
› chronic kidney disease (N18.-)
› respiratory distress (J80, R06.-)
› seizure disorder (G40.-, R56.9)
E20.811Secondary hypoparathyroidism in diseases classified elsewhere
Code First: underlying condition, if known
E20.812Autoimmune hypoparathyroidism
Code First: , if applicable, underlying condition such as:
› autoimmune polyglandular failure (E31.0)
› Schmidt's syndrome (E31.0)
E20.818Other specified hypoparathyroidism due to impaired parathyroid hormone secretion
› Familial isolated hypoparathyroidism
E20.819Hypoparathyroidism due to impaired parathyroid hormone secretion, unspecified
E20.89Other specified hypoparathyroidism
› Familial hypoparathyroidism
E20.9Hypoparathyroidism, unspecified
› Parathyroid tetany
E21Hyperparathyroidism and other disorders of parathyroid gland
Excludes 1: adult osteomalacia (M83.-)
› ectopic hyperparathyroidism (E34.2)
› hungry bone syndrome (E83.81)
› infantile and juvenile osteomalacia (E55.0)
Excludes 2: familial hypocalciuric hypercalcemia (E83.52)
E21.0Primary hyperparathyroidism
› Hyperplasia of parathyroid
› Osteitis fibrosa cystica generalisata [von Recklinghausen's disease of bone]
E21.1Secondary hyperparathyroidism, not elsewhere classified
Excludes 1: secondary hyperparathyroidism of renal origin (N25.81)
E21.2Other hyperparathyroidism
› Tertiary hyperparathyroidism
Excludes 1: familial hypocalciuric hypercalcemia (E83.52)
E21.3Hyperparathyroidism, unspecified
E21.4Other specified disorders of parathyroid gland
E21.5Disorder of parathyroid gland, unspecified
E22Hyperfunction of pituitary gland
Excludes 1: Cushing's syndrome (E24.-)
› Nelson's syndrome (E24.1)
› overproduction of ACTH not associated with Cushing's disease (E27.0)
› overproduction of pituitary ACTH (E24.0)
› overproduction of thyroid-stimulating hormone (E05.8-)
E22.0Acromegaly and pituitary gigantism
› Overproduction of growth hormone
Excludes 1: constitutional gigantism (E34.4)
› constitutional tall stature (E34.4)
› increased secretion from endocrine pancreas of growth hormone-releasing hormone (E16.8)
E22.1Hyperprolactinemia
Use Additional Code: code for adverse effect, if applicable, to identify drug (T36-T50) with fifth or sixth character 5)
E22.2Syndrome of inappropriate secretion of antidiuretic hormone
E22.8Other hyperfunction of pituitary gland
› Central precocious puberty
E22.9Hyperfunction of pituitary gland, unspecified
E23Hypofunction and other disorders of the pituitary gland
Includes: the listed conditions whether the disorder is in the pituitary or the hypothalamus
Excludes 1: postprocedural hypopituitarism (E89.3)
› short stature due to endocrine disorder (E34.3-)
E23.0Hypopituitarism
› Fertile eunuch syndrome
› Hypogonadotropic hypogonadism
› Idiopathic growth hormone deficiency
› Isolated deficiency of gonadotropin
› Isolated deficiency of growth hormone
› Isolated deficiency of pituitary hormone
› Kallmann's syndrome
› Lorain-Levi short stature
› Necrosis of pituitary gland (postpartum)
› Panhypopituitarism
› Pituitary cachexia
› Pituitary insufficiency NOS
› Pituitary short stature
› Sheehan's syndrome
› Simmonds' disease
E23.1Drug-induced hypopituitarism
Use Additional Code: code for adverse effect, if applicable, to identify drug (T36-T50) with fifth or sixth character 5)
E23.2Diabetes insipidus
Excludes 1: nephrogenic diabetes insipidus (N25.1)
E23.3Hypothalamic dysfunction, not elsewhere classified
Excludes 1: Prader-Willi syndrome (Q87.11)
› Russell-Silver syndrome (Q87.19)
E23.6Other disorders of pituitary gland
› Abscess of pituitary
› Adiposogenital dystrophy
E23.7Disorder of pituitary gland, unspecified
E24Cushing's syndrome
Excludes 1: congenital adrenal hyperplasia (E25.0)
E24.0Pituitary-dependent Cushing's disease
› Overproduction of pituitary ACTH
› Pituitary-dependent hypercorticalism
E24.1Nelson's syndrome
E24.2Drug-induced Cushing's syndrome
Use Additional Code: code for adverse effect, if applicable, to identify drug (T36-T50) with fifth or sixth character 5)
E24.3Ectopic ACTH syndrome
E24.4Alcohol-induced pseudo-Cushing's syndrome
E24.8Other Cushing's syndrome
E24.9Cushing's syndrome, unspecified
E25Adrenogenital disorders
Includes: adrenogenital syndromes, virilizing or feminizing, whether acquired or due to adrenal hyperplasia consequent on inborn enzyme defects in hormone synthesis
› Female adrenal pseudohermaphroditism
› Female heterosexual precocious pseudopuberty
› Male isosexual precocious pseudopuberty
› Male macrogenitosomia praecox
› Male sexual precocity with adrenal hyperplasia
› Male virilization (female)
Excludes 1: indeterminate sex and pseudohermaphroditism (Q56)
› chromosomal abnormalities (Q90-Q99)
E25.0Congenital adrenogenital disorders associated with enzyme deficiency
› Congenital adrenal hyperplasia
› 21-Hydroxylase deficiency
› Salt-losing congenital adrenal hyperplasia
E25.8Other adrenogenital disorders
› Idiopathic adrenogenital disorder
Use Additional Code: code for adverse effect, if applicable, to identify drug (T36-T50) with fifth or sixth character 5)
E25.9Adrenogenital disorder, unspecified
› Adrenogenital syndrome NOS
E26Hyperaldosteronism
E26.0Primary hyperaldosteronism
E26.01Conn's syndrome
Code Also: adrenal adenoma (D35.0-)
E26.02Glucocorticoid-remediable aldosteronism
› Familial aldosteronism type I
E26.09Other primary hyperaldosteronism
› Primary aldosteronism due to adrenal hyperplasia (bilateral)
E26.1Secondary hyperaldosteronism
E26.8Other hyperaldosteronism
E26.81Bartter's syndrome
E26.89Other hyperaldosteronism
E26.9Hyperaldosteronism, unspecified
› Aldosteronism NOS
› Hyperaldosteronism NOS
E27Other disorders of adrenal gland
E27.0Other adrenocortical overactivity
› Overproduction of ACTH, not associated with Cushing's disease
› Premature adrenarche
Excludes 1: Cushing's syndrome (E24.-)
E27.1Primary adrenocortical insufficiency
› Addison's disease
› Autoimmune adrenalitis
Excludes 1: Addison only phenotype adrenoleukodystrophy (E71.528)
› amyloidosis (E85.-)
› tuberculous Addison's disease (A18.7)
› Waterhouse-Friderichsen syndrome (A39.1)
E27.2Addisonian crisis
› Adrenal crisis
› Adrenocortical crisis
E27.3Drug-induced adrenocortical insufficiency
Use Additional Code: code for adverse effect, if applicable, to identify drug (T36-T50) with fifth or sixth character 5)
E27.4Other and unspecified adrenocortical insufficiency
Excludes 1: adrenoleukodystrophy [Addison-Schilder] (E71.528)
› Waterhouse-Friderichsen syndrome (A39.1)
E27.40Unspecified adrenocortical insufficiency
› Adrenocortical insufficiency NOS
› Hypoaldosteronism
E27.49Other adrenocortical insufficiency
› Adrenal hemorrhage
› Adrenal infarction
E27.5Adrenomedullary hyperfunction
› Adrenomedullary hyperplasia
› Catecholamine hypersecretion
E27.8Other specified disorders of adrenal gland
› Abnormality of cortisol-binding globulin
E27.9Disorder of adrenal gland, unspecified
E28Ovarian dysfunction
Excludes 1: isolated gonadotropin deficiency (E23.0)
› postprocedural ovarian failure (E89.4-)
E28.0Estrogen excess
Use Additional Code: code for adverse effect, if applicable, to identify drug (T36-T50) with fifth or sixth character 5)
E28.1Androgen excess
› Hypersecretion of ovarian androgens
Use Additional Code: code for adverse effect, if applicable, to identify drug (T36-T50) with fifth or sixth character 5)
E28.2Polycystic ovarian syndrome
› Sclerocystic ovary syndrome
› Stein-Leventhal syndrome
E28.3Primary ovarian failure
Excludes 1: pure gonadal dysgenesis (Q99.1)
› Turner's syndrome (Q96.-)
E28.31Premature menopause
E28.310Symptomatic premature menopause
› Symptoms such as flushing, sleeplessness, headache, lack of concentration, associated with premature menopause
E28.319Asymptomatic premature menopause
› Premature menopause NOS
E28.39Other primary ovarian failure
› Decreased estrogen
› Resistant ovary syndrome
E28.8Other ovarian dysfunction
› Ovarian hyperfunction NOS
Excludes 1: postprocedural ovarian failure (E89.4-)
E28.9Ovarian dysfunction, unspecified
E29Testicular dysfunction
Excludes 1: androgen insensitivity syndrome (E34.5-)
› azoospermia or oligospermia NOS (N46.0-N46.1)
› isolated gonadotropin deficiency (E23.0)
› Klinefelter's syndrome (Q98.0-Q98.1, Q98.4)
E29.0Testicular hyperfunction
› Hypersecretion of testicular hormones
E29.1Testicular hypofunction
› Defective biosynthesis of testicular androgen NOS
› 5-delta-Reductase deficiency (with male pseudohermaphroditism)
› Testicular hypogonadism NOS
Use Additional Code: code for adverse effect, if applicable, to identify drug (T36-T50) with fifth or sixth character 5)
Excludes 1: postprocedural testicular hypofunction (E89.5)
E29.8Other testicular dysfunction
E29.9Testicular dysfunction, unspecified
E30Disorders of puberty, not elsewhere classified
E30.0Delayed puberty
› Constitutional delay of puberty
› Delayed sexual development
E30.1Precocious puberty
› Precocious menstruation
Excludes 1: Albright (-McCune) (-Sternberg) syndrome (Q78.1)
› central precocious puberty (E22.8)
› congenital adrenal hyperplasia (E25.0)
› female heterosexual precocious pseudopuberty (E25.-)
› male isosexual precocious pseudopuberty (E25.-)
E30.8Other disorders of puberty
› Premature thelarche
E30.9Disorder of puberty, unspecified
E31Polyglandular dysfunction
Excludes 1: ataxia telangiectasia [Louis-Bar] (G11.3)
› dystrophia myotonica [Steinert] (G71.11)
› pseudohypoparathyroidism (E20.1)
E31.0Autoimmune polyglandular failure
› Schmidt's syndrome
E31.1Polyglandular hyperfunction
Excludes 1: multiple endocrine adenomatosis (E31.2-)
› multiple endocrine neoplasia (E31.2-)
E31.2Multiple endocrine neoplasia [MEN] syndromes
› Multiple endocrine adenomatosis
Code Also: any associated malignancies and other conditions associated with the syndromes
E31.20Multiple endocrine neoplasia [MEN] syndrome, unspecified
› Multiple endocrine adenomatosis NOS
› Multiple endocrine neoplasia [MEN] syndrome NOS
E31.21Multiple endocrine neoplasia [MEN] type I
› Wermer's syndrome
E31.22Multiple endocrine neoplasia [MEN] type IIA
› Sipple's syndrome
E31.23Multiple endocrine neoplasia [MEN] type IIB
E31.8Other polyglandular dysfunction
E31.9Polyglandular dysfunction, unspecified
E32Diseases of thymus
Excludes 1: aplasia or hypoplasia of thymus with immunodeficiency (D82.1)
› myasthenia gravis (G70.0)
E32.0Persistent hyperplasia of thymus
› Hypertrophy of thymus
E32.1Abscess of thymus
E32.8Other diseases of thymus
Excludes 1: aplasia or hypoplasia with immunodeficiency (D82.1)
› thymoma (D15.0)
E32.9Disease of thymus, unspecified
E34Other endocrine disorders
Excludes 1: pseudohypoparathyroidism (E20.1)
E34.0Carcinoid syndrome
May be used as an additional code to identify functional activity associated with a carcinoid tumor.
E34.1Other hypersecretion of intestinal hormones
E34.2Ectopic hormone secretion, not elsewhere classified
Excludes 1: ectopic ACTH syndrome (E24.3)
E34.3Short stature due to endocrine disorder
Excludes 1: achondroplastic short stature (Q77.4)
› hypochondroplastic short stature (Q77.4)
› nutritional short stature (E45)
› pituitary short stature (E23.0)
› progeria (E34.8)
› renal short stature (N25.0)
› Russell-Silver syndrome (Q87.19)
› short-limbed stature with immunodeficiency (D82.2)
› short stature (child) (R62.52)
› short stature in specific dysmorphic syndromes - code to syndrome - see Alphabetical Index
› short stature NOS (R62.52)
E34.30Short stature due to endocrine disorder, unspecified
E34.31Constitutional short stature
› Constitutional delay of growth, puberty, or maturation
E34.32Genetic causes of short stature
E34.321Primary insulin-like growth factor-1 (IGF-1) deficiency
› Acid-labile subunit gene (IGFALS) defect
› Growth hormone gene 1 (GH1) defect with growth hormone neutralizing antibodies
› Growth hormone insensitivity syndrome (GHIS)
› Insulin-like growth factor 1 gene (IGF1) defect
› Laron type short stature
› Severe primary insulin-like growth factor-1 deficiency (SPIGFD)
› Signal transducer and activator of transcription 5B gene (STAT5b) defect
E34.322Insulin-like growth factor-1 (IGF-1) resistance
› Genetic syndrome with resistance to insulin-like growth factor-1
› Insulin-like growth factor-1 receptor (IGF-1R) defect
› Post-insulin-like growth factor-1 receptor signaling defect
E34.328Other genetic causes of short stature
› Short stature due to ACAN gene variant
› Short stature due to aggrecan deficiency
› Short stature due to NPR-2 gene variant
E34.329Unspecified genetic causes of short stature
E34.39Other short stature due to endocrine disorder
E34.4Constitutional tall stature
› Constitutional gigantism
E34.5Androgen insensitivity syndrome
E34.50Androgen insensitivity syndrome, unspecified
› Androgen insensitivity NOS
E34.51Complete androgen insensitivity syndrome
› Complete androgen insensitivity
› de Quervain syndrome
› Goldberg-Maxwell syndrome
E34.52Partial androgen insensitivity syndrome
› Partial androgen insensitivity
› Reifenstein syndrome
E34.8Other specified endocrine disorders
› Pineal gland dysfunction
› Progeria
Excludes 2: pseudohypoparathyroidism (E20.1)
E34.9Endocrine disorder, unspecified
› Endocrine disturbance NOS
› Hormone disturbance NOS
E35Disorders of endocrine glands in diseases classified elsewhere
Code First: underlying disease, such as:
› late congenital syphilis of thymus gland [Dubois disease] (A50.9)
Use Additional Code: code, if applicable, to identify:
› sequelae of tuberculosis of other organs (B90.8)
Excludes 1: Echinococcus granulosus infection of thyroid gland (B67.3)
› meningococcal hemorrhagic adrenalitis (A39.1)
› syphilis of endocrine gland (A52.79)
› tuberculosis of adrenal gland, except calcification (A18.7)
› tuberculosis of endocrine gland NEC (A18.82)
› tuberculosis of thyroid gland (A18.81)
› Waterhouse-Friderichsen syndrome (A39.1)